Immunotherapy by immune checkpoint inhibitors (ICIs) has showed outstanding efficacy in the treatment of advanced non-small cell lung cancer (NSCLC). The combination of immunotherapy with anti-angioge

NIAID Data Ecosystem30

Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients

非小细胞肺癌精准治疗

液体活检临床决策

Aim: To understand physicians’ attitudes and behaviors regarding EGFR testing and retesting strategies in newly diagnosed metastatic non-small cell lung cancer patients. Materials & methods: Oncologis

Figshare2024-11-18 更新20

Patient genetic data.xlsx

非小细胞肺癌精准治疗

EGFR-TKI耐药性

NSCLC patients with EGFR mutations carrying PD-L1 TPS ≥ 50% after developing EGFR-TKI resistance

Figshare2023-04-20 更新30

Table_3_Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model.xlsx

免疫检查点抑制剂响应预测

非小细胞肺癌精准治疗

Due to the complex mechanisms affecting anti-tumor immune response, a single biomarker is insufficient to identify patients who will benefit from immune checkpoint inhibitors (ICIs) treatment. Therefo

NIAID Data Ecosystem30